Listed by the USPTO as BROWE, DAVID
Tech Center 1600 • Art Units: 1617 1632
This examiner grants 27% of resolved cases
BROWE, DAVID examines in Tech Center 1600 and Art Unit 1617. His profile records 739 resolved cases, an allowance rate of 26.7%, and a median of 1428 days to allowance. Interviews show a 28.0% lift, making interview preparation a meaningful consideration even though the allowance result indicates substantial prosecution difficulty in the reported record.
The listed companies are Troy Corporation, Shandong University, and Syngenta AG. The associated firms are DORITY & MANNING, P.A., KLARQUIST SPARKMAN, LLP, and Arnold & Porter Kaye Scholer LLP. These organizations provide reference points for representative chemical and agricultural work, while the timing measure supports planning for prolonged prosecution.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16753567 | IMPLANTABLE BIOREACTOR AND METHODS FOR MAKING AND USING SAME | Final Rejection | THE JOHNS HOPKINS UNIVERSITY |
| 18703132 | SUBSTITUTED BENZAMIDES AS HERBICIDES | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18314808 | COMPOSITION FOR PENETRATING SUGAR BASED DELIVERY SYSTEM | Final Rejection | Evonik Operations GmbH |
| 15621627 | Glycosaminoglycan-Based Materials as an Engineered Biocompatible Cellular Matrix | Non-Final OA | Purdue Research Foundation |
| 18642539 | NANOFIBERS AND THEIR USE IN ENHANCING PARTICLE-BASED HYDROGEL SCAFFOLDS FOR REGENERATIVE MEDICINE AND TISSUE ENGINEERING | Non-Final OA | UNIVERSITY OF VIRGINIA PATENT FOUNDATION |
| 18151932 | IMPREGNATED COSMETIC ARTICLE WITH FIBERS AND SCREEN NET | Final Rejection | L'OREAL |
| 18713537 | METHOD FOR TREATING KERATIN SUBSTANCE OR FIBER FOR HEAD DECORATION PRODUCTS | Non-Final OA | KAO CORPORATION |
| 18718737 | LEVONORGESTREL BUTANOATE FORMULATION AND METHODS RELATING THERETO | Non-Final OA | SRI International |
| 18015160 | COMPOSITIONS WITH VIRUCIDAL AND/OR ANTIVIRAL ACTIVITY | Non-Final OA | SYMRISE AG |
| 18327740 | METHOD OF TREATING SCHIZOPHRENIA OR SCHIZOPHRENIFORM DISORDER | Non-Final OA | Curemark, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy26.7% of resolved applications examined by David Browe were allowed (739 resolved cases), compared with 34.1% across Art Unit 1617 over the last five years.
This examiner's interview lift is +28.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by David Browe took 1,428 days on average from filing to allowance.
David Browe examines applications in Art Unit 1617 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
